Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure

Teerlink, J. R. et al. (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure. Journal of the American College of Cardiology, 67(12), pp. 1444-1455. (doi: 10.1016/j.jacc.2016.01.031) (PMID:27012405)

120858.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Background: Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in healthy volunteers and in patients with chronic heart failure. Objectives: This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of OM in patients with acute heart failure (AHF). Methods: Patients admitted for AHF with left ventricular ejection fraction ≤40%, dyspnea, and elevated plasma concentrations of natriuretic peptides were randomized to receive a double-blind, 48-h intravenous infusion of placebo or OM in 3 sequential, escalating-dose cohorts. Results: In 606 patients, OM did not improve the primary endpoint of dyspnea relief (3 OM dose groups and pooled placebo: placebo, 41%; OM cohort 1, 42%; cohort 2, 47%; cohort 3, 51%; p = 0.33) or any of the secondary outcomes studied. In supplemental, pre-specified analyses, OM resulted in greater dyspnea relief at 48 h (placebo, 37% vs. OM, 51%; p = 0.034) and through 5 days (p = 0.038) in the high-dose cohort. OM exerted plasma concentration-related increases in left ventricular systolic ejection time (p < 0.0001) and decreases in end-systolic dimension (p < 0.05). The adverse event profile and tolerability of OM were similar to those of placebo, without increases in ventricular or supraventricular tachyarrhythmias. Plasma troponin concentrations were higher in OM-treated patients compared with placebo (median difference at 48 h, 0.004 ng/ml), but with no obvious relationship with OM concentration (p = 0.95). Conclusions: In patients with AHF, intravenous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated, it increased systolic ejection time, and it may have improved dyspnea in the high-dose group. (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure [ATOMIC-AHF]; NCT01300013).

Item Type:Articles
Glasgow Author(s) Enlighten ID:McMurray, Professor John and Cleland, Professor John
Authors: Teerlink, J. R., Felker, G. M., McMurray, J. J.V., Ponikowski, P., Metra, M., Filippatos, G. S., Ezekowitz, J. A., Dickstein, K., Cleland, J. G.F., Kim, J. B., Lei, L., Knusel, B., Wolff, A. A., Malik, F. I., and Wasserman, S. M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:Journal of the American College of Cardiology
Published Online:21 March 2016
Copyright Holders:Copyright © 2016 The American College of Cardiology Foundation
First Published:First published in Journal of the American College of Cardiology 67(12): 1444:1455
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record